07:31 AM EST, 03/03/2026 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) reported a Q4 net loss Tuesday of $0.30 per diluted share, narrower than a loss of $0.55 a year earlier.

Three analysts polled by FactSet expected a loss of $0.29.

As expected, no revenue for the quarter ended Dec. 31 was reported.

As of Dec. 31, the company said it had $317 million in cash, cash equivalents, and short-term investments, which will likely finance operations through potential avexitide commercialization and into 2028.

Amylyx Pharmaceuticals ( AMLX ) shares were down more than 3% in Tuesday premarket activity.